Format

Send to

Choose Destination
J Comp Eff Res. 2018 Mar;7(3):193-208. doi: 10.2217/cer-2017-0040. Epub 2018 Mar 13.

Development and validation of a claims-based approach to proxy ECOG performance status across ten tumor groups.

Author information

1
Global Patient Outcomes & Real World Evidence, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.
2
Outcomes Research, Truven Health Analytics, an IBM Company, 100 Phoenix Drive, Ann Arbor, MI 48108, USA.
3
Department of Health Policy and Management, Yale School of Public Health, 60 College Street, PO Box 208034, New Haven, CT 06510, USA.

Abstract

AIM:

To develop a claims-based prediction model of poor performance status (PS) in commercially insured and Medicare supplemental beneficiaries with cancer.

PATIENTS & METHODS:

Retrospective analysis was conducted of electronic medical records (EMR) from community oncology practices linked to MarketScan claims. Multivariable logistic regression predicted PS scores from the EMR using claims-based diagnostic and procedure codes.

RESULTS:

The study included 8442 patients diagnosed with cancer from 2007 to 2015. Overall, 8.1% of patients had poor EMR-based PS. Bootstrapping results from the final model showed sensitivity and specificity of approximately 75% with a predicted probability cutpoint = 0.078, c-statistic = 0.821 and pseudo-R2 = 0.25.

CONCLUSION:

Patients with poor PS can be identified in claims data. This prediction model enables future studies evaluating cancer treatments and outcomes to account for PS.

KEYWORDS:

cancer; claims data; performance status; validation

PMID:
29533694
DOI:
10.2217/cer-2017-0040

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center